KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Liabilities and Shareholders Equity: 2017-2024

Historic Liabilities and Shareholders Equity for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $101.4 million.

  • Aquestive Therapeutics' Liabilities and Shareholders Equity rose 48.75% to $163.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $460.9 million, marking a year-over-year increase of 11.20%. This contributed to the annual value of $101.4 million for FY2024, which is 76.64% up from last year.
  • Aquestive Therapeutics' Liabilities and Shareholders Equity amounted to $101.4 million in FY2024, which was up 76.64% from $57.4 million recorded in FY2023.
  • Over the past 5 years, Aquestive Therapeutics' Liabilities and Shareholders Equity peaked at $101.4 million during FY2024, and registered a low of $57.1 million during FY2022.
  • Its 3-year average for Liabilities and Shareholders Equity is $72.0 million, with a median of $57.4 million in 2023.
  • In the last 5 years, Aquestive Therapeutics' Liabilities and Shareholders Equity declined by 19.87% in 2020 and then skyrocketed by 76.64% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $62.9 million in 2020, then dropped by 1.42% to $62.0 million in 2021, then fell by 7.94% to $57.1 million in 2022, then climbed by 0.61% to $57.4 million in 2023, then soared by 76.64% to $101.4 million in 2024.